Evaluation of Virtual Course to Increase Knowledge in Sexual Harassment,Prevention and Sanction Policies of a University

March 23, 2020 updated by: Mireya Reyna Martínez Ipanaqué, Universidad Peruana Cayetano Heredia

Evaluation of a Virtual Course to Increase Knowledge in Sexual Harassment, Prevention and Sanction Policies of Cayetano Heredia Peruvian University in Pupils of the Faculty of Public Health and Administration: a Randomized Controlled Trial

Sexual harassment is the behavior of sexual or sexist connotation unwanted by the affected person. Despite being considered as gender-based violence, victims of sexual harassment can be of both sexes. The university is the most frequent place where university students suffer sexual harassment. Law No. 27942 - "Ley de Prevención y Sanción del Hostigamiento Sexual" and its amendments, includes training and prevention in sexual harassment. The Universidad Peruana Cayetano Heredia (UPCH) has a regulation for the prevention and punishment of sexual harassment. Education through the use of Information and Communications Technologies (ICT) is presented as an alternative to face-to-face classes, optimizing resources and achieving greater scope. The early, mandatory and massive dissemination at the university of a training in sexual harassment could be achieved through a virtual course. However, there is little research on the evaluation of the effectiveness of prevention programs in sexual violence in university students. The objective is to prove that taking a virtual course about sexual harassment, prevention and sanction policies of the UPCH can achieve a greater or same knowledge of the subject in the students of the UPCH, compared to a face-to-face course. The study design is a randomized controlled trial to assess the level of knowledge in this subject, whose control group is provided classes in face-to-face mode. Also, both modalities of the course will include a survey with Likert scale to measure the degree of satisfaction with the course taken. And finally, it includes a qualitative study through focus groups with the university students of the classroom and virtual classes to know their appreciations of both modalities of the course.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Main Objective:

Compare the improvement of knowledge about sexual harassment, prevention and sanction policies of the UPCH of the asynchronous virtual course with the face-to-face course in students of the UPCH.

Study Design:

A randomized control trial will compare the improvement of knowledge among who received asynchronous virtual classes and those who received face-to-face classes by applying a pre-test and 2 post-test. The pre-test and the first post-test will be taken the day of the intervention and the second post-test will be taken after a month to measure knowledge retention.

To measure the degree of satisfaction with the course modality, the intervention's day the students will take a survey with Likert scale. And separately, some students of the intervention and control group will be interview in focus groups to know their appreciations about the satisfaction perceived with the modality of the course taken.

Population:

Undergraduate university students enrolled in the 2019-II period of the Faculty of Public Health and Administration (FASPA).

Sample:

For the randomized control trial, a sample of 67 participants per group was calculated with a significance of 95%, a power of 80% and a loss of follow-up rate of 6%, to show a difference of 7% in the scores of knowledge of sexual harassment between the two groups.

For the qualitative analysis of the focus groups, for each course modality, there will be two sessions of 6 people who completed the course. However, focus groups will continue to be carried out until the sample becomes saturated, that is, until the information obtained from these meetings is redundant or the objectives of the study are clarified.

Group assignment:

Students of FASPA will be invited to participate by flyers and invitations in classrooms. Also, by e-mail they will receive an invitation with the informational consent form and a link to fill out a registration form for the ones who are interested in participating. If inclusion and exclusion criteria are met, students will be accepted to participate in the study and they will be randomly assigned to one of the two groups. Finally they will receive an e-mail confirming their participation and the available schedules for the classes.

Ethical considerations:

Students who are registered and want to participate but do not meet the inclusion and exclusion criteria of the study, will be offered the virtual course restricting the access to the evaluations.

Every participant will receive the informational consent form. Data confidentiality will be maintained. Personal identifiers will be stored in a separate database, which will be password protected and accessible only to the research team. At the end of this project, UPCH will be able to dispose of the virtual course developed in this study for the purposes that may be appropriate.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
93

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Peru
    • Lima
      • San Martín De Porres, Lima, Peru, 15102
        • Universidad Peruana Cayetano Heredia

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

14 years to 50 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Undergraduate university students enrolled in the 2019-II period of FASPA

Exclusion Criteria:

  • Students who have already taken a course on sexual harassment
  • Exchange students (foreigners)
  • Students who have not completed the pre-test and post-tests

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Intervention
Participants will be gathered in a classroom with computers to receive an asynchronous virtual class of 45 minutes, 1 pre-test, 1 post-test and satisfaction surveys with Likert scale. This session will take 2 hours approximately. After a month, they will take a second post-test to measure retention of knowledge. The pre-test and post-tests are all the same and they all will be taken by using computer.
Other: Asynchronous Virtual Class
Every student will have the access to a platform with an Asynchronous Virtual Class that will use the same PowerPoint Presentation of the intervention with an audio recorded by the principal investigator
Sham Comparator: Control
Participants will be gathered in a classroom with computers to receive a face-to-face class of 45 minutes, 1 pre-test, 1 post-test and satisfaction surveys with Likert scale. This session will take 2 hours approximately. After a month, they will take a second post-test to measure retention of knowledge. The pre-test and post-tests are all the same and they all will be taken by using computer.
Other: Face-to-face Class
The principal investigator will dictate a course about Sexual Harassment, Prevention and Sanction Policies of Cayetano Heredia Peruvian University using PowerPoint Presentation

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Level of Knowledge about sexual harassment
Time Frame: 3 months

Measured by the automatic score the student get after taking the tests in a web platform.

The instrument is a questionnaire made up of 20 multiple-choice questions about knowledge in sexual harassment, prevention and sanction policies of the university. Each correct question is worth 5 points so the scale range will be 0-100 points in total but then it will be converted to vigesimal score from 0 to 20 points, being the passing grade 11.00.
3 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Satisfaction with the course measured by a Likert-scale survey
Time Frame: 3 months
Number of positive responses / total number of questions. The instrument is a Likert-scale survey with 9 questions about how satisfied is the student with the class session, the trainer, the class duration, the web platform, the quality of the class and others. The possible answers are: "Nothing", "Something", "A lot" and "Totally". Being the positive responses "A lot" and "Totally".
3 months
Satisfaction with the course described by a qualitative analysis of focal groups
Time Frame: 3 months
The focal groups will be carried out with the students of the 2 course modalities, separately. The instrument for this focus group is a questionnaire about the satisfaction with the modality of the course, the content of the course and the fulfillment of expectations of the students on the course, the trainer and the web platform.
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Universidad Peruana Cayetano Heredia

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Mireya R Martínez Ipanaqué, B.E., Universidad Peruana Cayetano Heredia

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • Zapp D, Buelow R, Soutiea L, Berkowitz A, DeJong W. Exploring the Potential Campus-Level Impact of Online Universal Sexual Assault Prevention Education. J Interpers Violence. 2021 Mar;36(5-6):NP2324-NP2345. doi: 10.1177/0886260518762449. Epub 2018 Mar 26.
  • Banyard VL, Moynihan MM, Plante EG. Sexual violence prevention through bystander education: an experimental evaluation. J Community Psychol [Internet]. 2007 [cited 2019 Feb 20];35(4):463-481. Available from: http://www.ncdsv.org/images/Sex%20Violence%20Prevention%20through%20Bystander%20Education.pdf
  • Ley de Prevención y Sanción del Hostigamiento Sexual. Ley N° 27942. Publicado en el diario oficial El Peruano, (05 de Febrero de 2003).
  • Decreto legislativo que incorpora el delito de acoso, acoso sexual, chantaje sexual y difusión de imágenes, materiales audiovisuales o audios con contenido sexual al código penal, y modifica el procedimiento de sanción del hostigamiento sexual. Decreto Legislativo N° 1410. Publicado en el diario oficial El Peruano, (11 de Septiembre de 2018).
  • Bardales O, Ortiz Z. Hostigamiento sexual en mujeres y varones universitarios. Estudio exploratorio [Internet]. Lima: MIMP;2012 [cited 2019 Jan 14]. Available from: http://redin.pncvfs.gob.pe/images/publicacion2/hostigamiento-sexual-en-mujeres-y-varones-universitarios9.pdf
  • Sarmiento P, Marcelo Y, Revollar E. Aproximación a la problemática del hostigamiento sexual laboral contra mujeres. Supervisión a ministerios, gobiernos regionales y Poder Judicial [Internet]. Lima: Defensoría del Pueblo del Perú; 2018 [cited 2019 Jan 14] Serie Informe de Adjuntía - Informe N° 007 - 2018- DP/ADM. Available from: https://www.defensoria.gob.pe/wp-content/uploads/2018/07/Informe-de-Adjuntia-007-2018-DP-ADM-II.pdf
  • Loli S. La Prevención y Sanción del Hostigamiento Sexual. Módulo de asistencia técnica para el abordaje desde la perspectiva de género [Internet]. Lima: MIMDES; 2008 [cited 2019 Jan 20]. Available from: https://www.mimp.gob.pe/files/direcciones/dgignd/publicaciones/prevencion_sancion_hostigamiento_sexual_modulo_ACDI.pdf
  • Carvajal Z, Delvó P. Análisis comparativo de dos estudios sobre hostigamiento sexual en la población estudiantil de la universidad nacional. Rev Latinoam Derechos Humanos [Internet]. 2010 [cited 2019 Jan 22];21(2):83-104. Available from: http://www.revistas.una.ac.cr/index.php/derechoshumanos/article/view/1930/1832
  • Ministerio de Trabajo y Promoción del Empleo. Guía para prevenir el hostigamiento sexual en el ámbito laboral [Internet]. Lima: MTPE; 2011[cited 2019 Jan 20]. Available from: http://www.academia.edu/13809973/Ministerio_de_Trabajo_y_Promoción_del_Empleo

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 10, 2019

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
February 7, 2020

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
February 7, 2020

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 11, 2019

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 15, 2019

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 16, 2019

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
March 25, 2020

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 23, 2020

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2020

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 103921

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sexual Harassment

Clinical Trials on Asynchronous Virtual Class

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings